Lyell Immunopharma Inc (LYEL) Stock Price, Quote & News

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 695 0677

Website: www.lyell.com

Address:

201 Haskins Way, South San Francisco, United States

ZacksResearch Dec. 24 at 6:09 PM

Biotech momentum is BACK — and these names are already up big 👀🚀 $MLYS, $LYEL, $NKTR and $INSM are all up more than 50% in 2025, powered by clinical wins, FDA approvals, and M&A deals that are reviving confidence across the drug and biotech space heading into 2026. See why these high-flyers may still have room to grow 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-teaser-26257&ADID=SYND_STOCKTWITS_TWEET_2_2808693_TEASER_26257

0 · Reply

TalkMarkets Dec. 23 at 10:03 PM

#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436

1 · Reply

DanaHiggenbotham181 Dec. 23 at 3:20 AM

Lyell Immunopharma $LYEL +17% today as new ASH data showed its CAR-T therapy ronde-cel delivered an 83% overall response and 61% complete response in second-line large B-cell lymphoma!! 70% of complete responders maintained response at least 6 months.

0 · Reply

BearTamerTrading Dec. 23 at 1:51 AM

Market Alerts — Bear Tamer Trading Top Plays Recap | Part 3 of 3 🔥 $ZIM — Explosive overnight move with sustained strength, offering clean continuation setups. 🔥 $MGRT — Strong intraday breakout followed by fast pullbacks, perfect for momentum scalps. 🔥 $CETX — High relative volume with aggressive price expansion into the close. 🔥 $SBDS — Volatility spike with quick reversals, rewarding disciplined entries and exits. 🔥 $LYEL — Late-day momentum burst followed by consolidation, keeping traders engaged. Congrats to everyone who caught these live on Market Alerts today 💰👏 Here’s the proof we alerted them live ⬇️ https://youtube.com/@beartamertrading?si=WYjEXuNxu_Erjabv

4 · Reply

Peterson28 Dec. 23 at 12:18 AM

$LYEL Was the only one here when it was trading at 0.5 pre-RS. Loaded 800k shares pre RS and 40k post. Took profits today. What a good ride. Biggest gain for me this year. Thanks all for playing.

1 · Reply

Jumpinjackflash33 Dec. 22 at 9:07 PM

$FJET bring this party over to $LYEL.

0 · Reply

BearTamerTrading Dec. 22 at 8:40 PM

Congratulations to those who got the alert earlier 🥂🍾. Thank you for putting your trust in me 🚀🎉💥 $LYEL

0 · Reply

AStrokeOfLuck Dec. 22 at 8:18 PM

$LYEL

0 · Reply

Revaluation Dec. 22 at 6:51 PM

$LYEL Missed out big here selling too early. Congrats all

0 · Reply

topstockalerts Dec. 22 at 6:38 PM

$LYEL not bad today.. 🙌

0 · Reply

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Dec 7, 2025, 4:30 PM EST - 17 days ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 10, 2025, 7:30 AM EST - 6 weeks ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 3, 2025, 9:00 AM EST - 7 weeks ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Jul 25, 2025, 8:00 AM EDT - 5 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 22, 2025, 9:02 AM EDT - 5 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jun 23, 2025, 5:00 PM EDT - 6 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 17, 2025, 6:30 AM EDT - 6 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 9, 2025, 4:05 PM EDT - 7 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 4, 2025, 4:05 PM EDT - 7 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 8 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 1, 2025, 9:00 AM EDT - 8 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Apr 15, 2025, 9:00 AM EDT - 9 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Mar 11, 2025, 4:05 PM EDT - 10 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 11 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Jan 9, 2025, 9:00 AM EST - 1 year ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Jan 3, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022, 7:00 AM EST - 3 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

ZacksResearch Dec. 24 at 6:09 PM

0 · Reply

TalkMarkets Dec. 23 at 10:03 PM

1 · Reply

DanaHiggenbotham181 Dec. 23 at 3:20 AM

0 · Reply

BearTamerTrading Dec. 23 at 1:51 AM

4 · Reply

Peterson28 Dec. 23 at 12:18 AM

$LYEL Was the only one here when it was trading at 0.5 pre-RS. Loaded 800k shares pre RS and 40k post. Took profits today. What a good ride. Biggest gain for me this year. Thanks all for playing.

1 · Reply

Jumpinjackflash33 Dec. 22 at 9:07 PM

$FJET bring this party over to $LYEL.

0 · Reply

BearTamerTrading Dec. 22 at 8:40 PM

Congratulations to those who got the alert earlier 🥂🍾. Thank you for putting your trust in me 🚀🎉💥 $LYEL

0 · Reply

AStrokeOfLuck Dec. 22 at 8:18 PM

$LYEL

0 · Reply

Revaluation Dec. 22 at 6:51 PM

$LYEL Missed out big here selling too early. Congrats all

0 · Reply

topstockalerts Dec. 22 at 6:38 PM

$LYEL not bad today.. 🙌

0 · Reply

Jumpinjackflash33 Dec. 22 at 6:34 PM

$LYEL choose one or take both $AFJK. Wake up longs!!! Buying pressure on these tickers could equal massive trading gains.

0 · Reply

Jumpinjackflash33 Dec. 22 at 5:44 PM

$LYEL it has all the makings of an explosive move.

0 · Reply

Jumpinjackflash33 Dec. 22 at 5:42 PM

$LYEL can u say HOD on deck, new shorts hit the spike will give it fuel

0 · Reply

Jumpinjackflash33 Dec. 22 at 5:36 PM

$LYEL position taken. On watch.

0 · Reply

Mdugs Dec. 22 at 5:12 PM

$LYEL bid is $18?

0 · Reply

ASKING7 Dec. 22 at 5:08 PM

$LYEL Congrats folks!

0 · Reply

MaskedJoe Dec. 22 at 5:07 PM

$LYEL any news?

0 · Reply

Peterson28 Dec. 22 at 5:05 PM

$LYEL One of my biggest wins this year.

1 · Reply

Mdugs Dec. 22 at 5:01 PM

$LYEL wth!

0 · Reply

JohnTrack Dec. 16 at 11:06 AM

$LYEL headline flash hit!! https://www.rapidticker.com/news/lyel-sec-filing-1ce155

0 · Reply

Malgo Dec. 13 at 9:03 PM

$LYEL

0 · Reply

terra987 Dec. 12 at 6:46 AM

$LYEL opportunity is huge .... (chart from Lyells June 25 presentation)

0 · Reply

Market Cap	793.04M
Revenue (ttm)	60,000.00
Net Income (ttm)	-342.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-571,650.00%
Debt to Equity Ratio	0.00

Volume	137,400
Avg Vol	58,584
Day's Range	N/A - N/A
Shares Out	21.24M
Stochastic %K	51%
Beta	-0.11
Analysts	Sell
Price Target	$28.50